- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biotage AB (BIOT)
Biotage AB stock price live, this page displays ST BIOT stock exchange data. View the BIOT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biotage AB real time stock price chart below.
What Is the Biotage AB Stock Price Today?
The Biotage AB stock price today is 143.20.
What Is the Stock Symbol for Biotage AB?
The stock symbol for Biotage AB is ""BIOT.""
What Stock Exchange Does Biotage AB Trade On?
Biotage AB is listed and trades on the Stockholm stock exchange.
Is Biotage AB a Good Stock to Buy?
Determining whether Biotage AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIOT quote. (ISIN: SE0000454746)
What Is the Biotage AB Stock Price Today?
The Biotage AB stock price today is 143.20.
What Is the Stock Symbol for Biotage AB?
The stock symbol for Biotage AB is ""BIOT.""
What Stock Exchange Does Biotage AB Trade On?
Biotage AB is listed and trades on the Stockholm stock exchange.
Is Biotage AB a Good Stock to Buy?
Determining whether Biotage AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIOT quote. (ISIN: SE0000454746)
Stockholm
Currency in SEK
143.20
+0.20(+0.14%)
Closed·
Fair Value
An estimate of a Biotage AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
142.40
143.90
52 wk Range
81.60
202.20
Showing Biotage AB historical data. For real-time data please try another search
Fair Value
An estimate of a Biotage AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
142.40143.90
52 wk Range
81.60202.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BIOT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Biotage AB's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Biotage AB receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Biotage AB receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Biotage AB Company Profile
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company serves pharmaceutical and biotechnical companies, police and criminal investigators contract research and manufacturing organizations, academic laboratories, hospitals, and sports events, as well as diagnostics, clinical, environmental protection, food safety, clinical, and forensic industries. It operates in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
Biotage AB Earnings Call Summary for Q1/2025
- Q1 2025 revenue weaker than previous year due to manufacturing constraints and slowdown in analytical testing
- Gross margin stable at 63%; strong demand for peptide systems; growth in drug discovery and Chinese markets
- Adjusted EBITDA at 50 million SEK; net cash at 182 million SEK; operating costs increased to 254 million SEK
- Company anticipates short-term revenue volatility but remains confident in mid to long-term outlook
- Cost reduction benefits expected in Q2; focus on building foundation for future growth and exploring alternative market reach
Last Updated: 23/04/2025, 08:38
Read Full TranscriptCompare BIOT to Peers and Sector
Metrics to compare | BIOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 45.0x | 32.1x | −0.5x | |
PEG Ratio | 10.69 | −0.04 | 0.00 | |
Price/Book | 3.0x | 2.7x | 2.6x | |
Price / LTM Sales | 5.8x | 3.4x | 3.3x | |
Upside (Analyst Target) | −0.1% | 35.6% | 43.5% | |
Fair Value Upside | Unlock | 6.6% | 6.9% | Unlock |
Earnings
Latest Release
Aug 06, 2025
EPS / Forecast
-- / 0.6967
Revenue / Forecast
-- / 461.93M
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.